SavedAdd your journal

Journals / Turkish Journal of Hematology / 2015 / Cilt: 32 - Sayı: 4

Hematolojik Malignitelerde Kimerik Antijen Reseptör-T Hücre Tedavisi

Chimeric Antigen Receptor T Cell Therapy in Hematology

Pınar ATACA
ÖNDER ARSLAN
Pages
285–294
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This review summarizes the history of adoptive immunotherapy, adoptive immunotherapy using CARs, the CAR manufacturing process, preclinical and clinical studies, and the effectiveness and drawbacks of this strategy

📌 3 Key Takeaways

🎯
Objective & Hypothesis:It is well demonstrated that the immune system can control and eliminate cancer cells.
📊
Key Findings & Data:On 1 July 2014, the United States Food and Drug Administration granted 'breakthrough therapy' designation to anti-CD19 CAR T cell therapy.
💡
Conclusion & Impact:This review summarizes the history of adoptive immunotherapy, adoptive immunotherapy using CARs, the CAR manufacturing process, preclinical and clinical studies, and the effectiveness and drawbacks of this strategy
🔬Design:Review & Systematic Survey
📍Scope:2014 Verileri
⚙️Variables:Domain Parameters

Abstract

It is well demonstrated that the immune system can control and eliminate cancer cells. Immune-mediated elimination of tumor cells has been discovered and is the basis of both cancer vaccines and cellular therapies including hematopoietic stem cell transplantation. Adoptive T cell transfer has been improved to be more specific and potent and to cause less off-target toxicity. Currently, there are two forms of engineered T cells being tested in clinical trials: T cell receptor (TCR) and chimeric antigen receptor (CAR) modified T cells. On 1 July 2014, the United States Food and Drug Administration granted 'breakthrough therapy' designation to anti-CD19 CAR T cell therapy. Many studies were conducted to evaluate the benefits of this exciting and potent new treatment modality. This review summarizes the history of adoptive immunotherapy, adoptive immunotherapy using CARs, the CAR manufacturing process, preclinical and clinical studies, and the effectiveness and drawbacks of this strategy

Özet

İmmün sistemin kanser hücrelerini kontrol ve elimine etme özelliğine sahip olduğu gösterilmiştir. İmmün-kontrollü eliminasyonda kanser aşıları ve hematopoietik kök hücre naklini içeren sellüler terapiler bulunmaktadır. Adoptif T hücre transferi daha potent ve spesifiktir, hedef dışı toksisitesi azdır. Klinik çalışmalarda iki tür T hücresi test edilmektedir: T hücre reseptör ve kimerik antijen reseptör (KAR) modifiye T hücreleri. 1 Temmuz 2014'te Amerikan Gıda ve İlaç Dairesi anti-CD19 ŞAR modifiye T hücre tedavisini "çığır açan tedaviler" sınıfına almıştır. Bu yeni tedavi yöntemini ve etkilerini araştıran birçok çalışma yapılmıştır. Bu derleme adoptif immünoterapinin geçmişini, ŞAR modifiye T hücrelerini, üretim sürecini, klinik ve preklinik çalışmaları özetlemektedir

🔖

Cite This Article

ATACA, P., ARSLAN, Ö. (2015). Hematolojik Malignitelerde Kimerik Antijen Reseptör-T Hücre Tedavisi. Turkish Journal of Hematology, Cilt: 32 - Sayı: 4, 285–294. https://ajindex.com/articles/412518

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Sadelain M. CAR T cell therapy: the CD19 paradigm. ASH Annual Meeting, Orlando, FL, USA, 2014.
  2. Miller JS, Warren EH, van den Brink MR, Ritz J, Shlomchik WD, Murphy WJ, Barrett AJ, Kolb HJ, Giralt S, Bishop MR, Blazar BR, Falkenburg JH. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease Following Allogeneic HSCT: Graft-versus- Tumor/Leukemia Reaction. Biol. Blood Marrow Transplant 2010;16:565-586.
  3. Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 2009;21:233-240. Ehrlich P. Über den jetzigen Stand der Karzinomforschung. Ned Tijdschr Geneeskd 1909;5:273-290 (in German). Kim R, Emi M, Tanabe K. Cancer immunoediting from immune surveillance to immune escape. J Immunol 2007;121:1-14.
  4. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Ann Rev Immunol 2004;22:329-360.
  5. Chang AE, Shu S. Current status of adoptive immunotherapy of cancer. Crit Rev Oncol Hematol 1996;22:213-228.
  6. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD. IFN? and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001;410:1107-1111.
  7. Rosenberg SA, Aebersold P, Cornetta K, Kasid A, Morgan RA, Moen R, Karson EM, Lotze MT, Yang JC, Topalian SL, Merino MJ, Culver K, Miller AD, Blaese RM, Anderson WF. Gene transfer into humans -- immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Eng J Med 1990;323:570-578.
  8. Wieczorek A, Uharek L. Genetically modified T cells for the treatment of malignant disease. Transfus Med Hemother 2013;40:388-402.
  9. Jensen MC, Riddell SR. Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells. Immunol Rev 2014;257:127-144. June CH. Principles of adoptive T cell cancer therapy J Clin Inv 2007;117:1204-1212. Stauss HJ. Immunotherapy with CTLs restricted by nonself MHC. Immunol Today 1999;20:180-183.
  10. Cohen CJ, Li YF, El-Gamil M, Robbins PF, Rosenberg SA, Morgan RA. Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. Cancer Res 2007;67:3898-3903.
  11. Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, Kammula US, Royal RE, Sherry RM, Wunderlich JR, Lee CC, Restifo NP, Schwarz SL, C